Although both studies had the limitation of small sample sizes, they both confirmed that MSLN-targeted CAR-T therapy has clinical activity against advanced ovarian cancer, mesothelioma, pancreatic cancer, and other solid tumors that have failed multiple lines of treatment, providing a basis for further research. The gene discussed is MSLN; the disease is pancreatic neoplasm.